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Background and aims: Severe asthma is burdened by frequent exacerbations and use of oral
corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this
study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treat-
ment of these patients.
Methods: Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017
and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months
before mepolizumab were collected retrospectively. The evaluation parameters included: OCS
use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual
number of working days lost due to the disease. The primary objective was to compare the annual
total cost per patient pre- and post-MEP. Secondary outcomes included rates of exacerbations and
number of OCS-dependent patients.
Results: 106 patients were enrolled in the study: 46 male, median age 58 years. Mean annual cost
pre- and post-MEP (cost of biologic excluded) was V3996 and V1,527, respectively. Total savings
due to MEP resulted in V2469 (95%CI 1945–2993), 62% due to exacerbations reduction and 33%
due to productivity increase. Such savings could fund about 22% of the total cost of MEP for one
year. The introduction of MEP induced a clinical benefit by reducing both OCS-dependent patients
(OR ¼ 0.12, 95%CI 0.06–0.23) and exacerbation rate (RR ¼ 0.19, 95%CI 0.15–0.24).
Conclusions: Patients with severe eosinophilic asthma experienced a clinical benefit in asthma
control adding MEP to standard therapy. Biologic therapy can be, partially, funded by the savings
produced by patients’ improvement.
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Asthma, together with chronic obstructive pul-
monary disease (COPD), is the most frequent
chronic airway disease, affecting more than 300
million people worldwide,1 with a 17.5% increase
of diagnosis between 2006-2016.2 Among
patients with asthma, a percentage varying from
5 to 10%3 suffers from a form, defined as
“severe”,4 which cannot be controlled by the
inhaled therapy (inhaled corticosteroids/
bronchodilators; ICS/LABA/LAMA) administered
at maximal doses. Furthermore severe asthma
frequently requires the use of oral corticosteroids
(OCS). The type of asthma, defined as severe, is
burdened by serious clinical problems such as
frequent exacerbations,3 hospitalizations,3
intubation, and in rare cases even death.5 Other
clinically relevant comorbidities include: sleep
disorders,6 intolerance to physical exercise,
mood disorders,7 reduced productivity,8 and
increased health care spending.9 The frequent
use of OCS, even for short periods of time, adds
a relevantly increased risk of comorbidities (ie,
diabetes, osteoporosis, cataract, hypertension),10
which therefore inevitably become serious
burdens from both clinical and
pharmacoeconomic points of view.11
To achieve a better control of severe asthma,
thus reducing exacerbations and OCS use, several
biological drugs able to modulate the inflamma-
tory characteristics of asthma were developed and
marketed. Mepolizumab (MEP), an interleukin-5
antagonist, given monthly by subcutaneous
administration, was the first biological agent spe-
cifically commercialized for uncontrolled severe
eosinophilic asthma. Despite numerous random-
ized and real life trials that confirmed the efficacy
and safety of MEP,12 there are still some unclear
points, especially regarding the
pharmacoeconomic aspects, since the drug is
quite expensive.
In this study we analysed prospectively the ef-
fects of the introduction of MEP,13 for the
treatment of patients with severe eosinophilic
asthma, from an economic point of view,
analysing the variation of direct and indirect costs
related to the drug administration. Secondly, the
effects of the drug were analysed with regard tothe main outcomes, such as exacerbations and
OCS spare.METHODS
Patients
Patients 18 years old, referred to 8 asthma
clinics between May 1, 2017 and December 31,
2018, and treated with MEP (1 vial 100 mg sub-
cutaneously/4 weeks), were enrolled in the study
and followed-up for 12 months (Post period). All
patients treated in the above mentioned period in
involved clinics have been considered in the study;
no patients have been discarded.
Asthma had been diagnosed clinically, func-
tionally (with a documented bronchodilation/
provocation) test, fractional nitric oxide (FeNO),
Asthma Control Test (ACT); all patients met the
criteria for severe uncontrolled asthma diagnosis
according to American Thoracic Society.European
Respiratory Society (ATS/ERS) guidelines4 as well
as MEP prescription criteria according to the
Italian Drug Agency. In particular, it was required
an eosinophilic count of at least 300/mL in the
year before MEP treatment, and of 150/mL before
the first MEP injection.
The relevant clinical information were collected
prospectively during the follow-up period, and the
same data were collected retrospectively in the 12
months before starting mepolizumab treatment
(Pre-MEP period). The main evaluated parameters
included: OCS mean daily dose, number of exac-
erbations/hospitalizations, comorbidity, and
annual number of working days lost due to the
disease.
For the analysis of the clinical outcomes, exac-
erbation and hospitalization rates were defined as
the number of events divided by the person-years
(PY) of follow-up (pre- and after 1 year of MEP).
Length of stay (LOS) in hospital was defined, for
each episode, as the number of days of direct
patient care (minimum 1 day) from admission to
discharge. The total cost of resource consumption,
drug therapies, and productivity loss were calcu-
lated both in the pre- and after 1 year period of
treatment to estimate the impact due to introduc-
tion of MEP. All patients signed an informed con-
sent for the treatment of personal data, which were
anonymized.
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Categorical variables are expressed as counts
and percentages, continuous variables are sum-
marized using median and interquartile range
(IQR), mean and standard deviation (SD) were also
reported if normally distributed (normality was
tested using Shapiro-Wilk test), and number of
events (exacerbation with or without hospitaliza-
tion) are expressed as rates (ie, number of events
per PY). Difference between pre- and post-MEP
treatment were tested using Fisher exact test for
categorical variables, Wilcoxon test for the
continuous one (Welch test is also performed in
case of normality) and Poisson test for rates.
Furthermore, to quantify the agreement between
inhaled corticosteroid/long-acting beta agonist
(ICS/LABA) therapy prior to and after the intro-
duction of mepolizumab, we used Cohen’s
kappa,14 in order to measure the agreement
between the treatment categories pre- and post-
MEP. Specific relative effect measures were also
presented with 95% confidence intervals (CI):
odds ratio (OR) for categorical outcomes, rate
ratio (RR) for rates, and absolute difference for
continuous outcomes (using a generalized linear
model, family ¼ gamma, link function ¼ identity).
All statistical analyses were performed using R (R
Core Team 2018).
Economic evaluation
The impact of the MEP treatment was evaluated
considering 1 subcutaneous 100 mg vial every 4
weeks.15 The cost for each treatment cycle was
calculated according to the ex-factory price,16
applying the mandatory discount (5% þ 5%
reduction) and price reductions negotiated
among the pharmaceutical company, Local
Health Units, and Hospital Units.17 The cost of
ICS/LABA, OCS, long-acting muscarinic
antagonist (LAMA), antileukotrienes, and
gastroesophageal reflux disease (GERD)
therapies was calculated using the reference
price established by negotiation for each
product package18 and for the specific posology
for each patient (Table A 1). The use of OCS was
expressed in prednisone dose equivalents;
hence, only the cost of prednisone was
considered, assuming the best package fitting
the daily dose. The cost of GERD therapy was
calculated according to specific treatmentreported in the database considering 4 weeks in
acute phase (maximum dose) followed by
maintenance with halved dose. When not
specified, the mean of all reported treatments
was considered as proxy.
The tariff of V 300 for an emergency room visit
was applied for exacerbations not needing hospi-
talization,19 excluding additional drugs since all
patients were already treated with OCS. The cost
for each hospitalization was estimated in V
1939.18, calculated according to our Diagnosis
Related Group 96 (Bronchitis and asthma, > 17
years with complications) and 97 (Bronchitis and
asthma, > 17 years without complications) tariffs,
weighted for the number of hospital admissions
(both ordinary and day-hospital) in Italy.20
Each day lost due to the disease was valued
using the cost of paid and unpaid (household ac-
tivities, caring for family members and others, and
volunteering) work, specific for age and sex21
updated to 201722 (Table A 2). For non-workers
(students, retired, or unemployed) only the total
length of stay in hospital was multiplied by the cost
of unpaid work.RESULTS
A total of 106 patients was enrolled in the study:
46 men (43.4%) and 60 women (56.6%), mean age
57.35 years (SD ¼ 10.56; median 58, IQR: 52.25–
65). All patients were included in the analysis, and
none was excluded due to missing data or clinical
response to the drug. During the observation
period we do not have any patients withdrawn
from treatment.
The comparison between pre- and post-MEP
periods for all clinical outcomes considered in the
analysis is detailed in Table 1. The introduction of
MEP showed a clinical benefit, significantly
reducing both the proportion of patients treated
with OCS (OR ¼ 0.12, 95% CI 0.06–0.231), and
mean daily OCS consumption in OCS-dependent
patients (4.73 mg, 95% CI -7.13 – 2.24). The
annual exacerbation rate decreased from 4.085
events per PY pre-MEP to 0.774 with MEP
(RR ¼ 0.189; 95% CI 0.148–0.24); in both periods,
exacerbations not needing hospitalization
accounted for about 90% of all events. Mean
hospital LOS per episode resulted slightly longer
Pre period Postperiod Post vs pre (95% CI) p-value
OCS - dependent patients, N (%) 84 (79.2%) 33 (31.1%) OR ¼ 0.12 (0.06–0.231) <0.0001
OCS daily dosea, mg 10 (5–
13.75)
5 (5–10) D ¼ 4.73 (7.13– 2.24) 0.0002
Total exacerbation rate (events per
PY)
4.085 0.774 RR ¼ 0.189 (0.148–0.24) <0.0001
Not needing hospitalization 3.699 0.717 RR ¼ 0.194 (0.15–0.248) <0.0001
Needing hospitalization 0.387 0.057 RR ¼ 0.146 (0.051–0.347) <0.0001
LOS per episode (days) 5.5 (3–8) 7 (6–10) D ¼ 1.41 (2.65–10.06) 0.61
Patients with lost working days N (%) 67 (63.2%) 32 (31.2%) OR ¼ 0.253 (0.136–0.463) <0.0001
Working days lost 15 (10–
23.5)
4 (2–6.25) D ¼ 11.87 (16.87–
7.64)
<0.0001
Table 1. Comparison of clinical outcome between the year before (pre-) and the year after (post-) MEP CI: confidence interval; LOS: length of
stay; MEP: mepolizumab; OCS: oral corticosteroids; OR: odds ratio; PY: person-years; RR: rate ratio a. Only OCS- dependent patients considered
Mean (SD)
EXACERBATIONS 12 months 4.1 (2.7)
HOSPITALIZATIONS 12 months 0.4 (0.6)
FEV1% 70 (20)
FEV1 L 2.07 (0.78)
FVC % 87 (18)
FVC L 3.12 (1.02)




OCS dependent (%) 84 (79)
OCS dosec 9.5 (8.5)
Table 2. Clinical patients’ characteristics at baseline Data are expressed as mean and standard deviation if not already specified. a. (blood eosinophils/
mcl) value expressed in geometric mean and SD b. Bronchodilation test has been performed in 41 patients, the other have a provocation positivity test c. mg of
prednisone or equivalent
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7 ¼ days); however, the uncertainty in the absolute
difference was high (1.41 days, 95% CI -2.65–
10.06) (Table 2). Finally, MEP achieved a better
control of disease symptoms since the proportion
of patients losing working days due to
hospitalizations or disease exacerbations
decreased from 63.2% in the pre-MEP period to31.2% in the post-MEP period (OR ¼ 0.253, 95%
CI 0.136–0.463). Furthermore, the number of
working days lost decreased significantly after
starting MEP (11.87 days, 95% CI -16.87– 7.64).
No differences were observed in the prevalence
of comorbidities recorded in the study pre- and
post-introduction of MEP (Table 3): rhinitis
Pre period Post period OR post vs pre (95% CI) p-value
Rhinitis, N (%) 74 (69.8%) 69 (65.1%) 0.807 (0.435–1.493) 0.5578
Polyposis, N (%) 65 (61.3%) 61 (57.5%) 0.856 (0.476–1.535) 0.6749
GERD, N (%) 35 (33.0%) 31 (29.2%) 0.839 (0.449–1.564) 0.6565
Dermatitis, N (%) 4 (3.8%) 4 (3.8%) 1 (0.181–5.523) >0.9999
Table 3. Comparison of main comorbidities between the year before and the year after starting MEP CI: confidence interval; GERD:
gastroesophageal reflux disease; MEP: mepolizumab; OR: odds ratio
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(OR ¼ 0.856, 95% CI 0.476–1.535), GERD
(OR ¼ 0.839, 95% CI 0.449–1.564), or dermatitis
(OR ¼ 1, 95% CI 0.181–5.523). As expected, the
introduction of MEP did not influence the dose of
inhaled therapy with ICS/LABA (Table A 3). There
was an almost perfect concordance between the
ICS/LABA therapy pre- and post-MEP
(kappa ¼ 0.837, 95% CI 0.758–0.917, p < 0.0001).Pre period
Drug therapy V 1163 (1087–
1239)
V
ICS/LABA V 706 (676–737) V
OCS V 75 (63–87) V
LAMA V 280 (223–338) V
Antileukotrienes V 78 (58–98) V
GERD V 24 (16–31) V
Exacerbations management V 1859 (1561–
2158)
V
Without hospitalizations V 1109 (959–1260) V
With hospitalizations V 750 (505–995) V
Productivity loss V 974 (724–1224) V
Paid work V 598 (437–759) V
Unpaid work V 376 (265–487) V
Total cost (MEP excluded) V 3996 (3517–
4476)
V




Table 4. Total annual cost pre- and post-MEP, data are reported as me
gastroesophageal reflux disease; LABA: long-acting beta-adrenoceptor agonist;
corticosteroidsThe mean annual cost pre- and post-MEP
introduction is reported in Table 4, split in the 3
main domains considered in the analysis: drugs,
exacerbation management, and productivity loss.
Excluding the cost of MEP, total savings due to
the added treatment resulted in V 2469 per
patient corresponding to a relative reduction
of 61.8% (Fig. 1). Most of the savings was due
to exacerbation reduction (-V 1529), followed byPost period Post vs pre
1035 (952–1117) -V 128 (239– 17))
696 (645–747) -V 10 (69–49)
20 (13–27) -V 55 (69– 41)
258 (201–315) -V 22 (103–58)
40 (24–56) -V 38 (63– 13)
21 (14–29) -V 2 (13–8)
331 (210–451) -V 1529 (1850– 1208)
221 (150–291) -V 889 (-1065– 723)
110 (9–211) -V 640 (904– 376)
162 (84–239) -V 812 (1074– 551)
97 (51–144) -V 500 (668– 333)
64 (30–99) -V 312 (428– 196)




an (95% confidence interval) ICS: inhaled corticosteroids; GERD:
LAMA: long-acting muscarinic antagonist; MEP: mepolizumab; OCS: oral
Fig. 1 Annual cost reduction per patients after mepolizumab introduction (MEP cost excluded)
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treatment, the total cost in the after period
amounts to V 12,975 per patient, corresponding
to an incremental cost (post vs pre period) of V
8979.DISCUSSION
The results herein described, using the pro-
spective and retrospective data collected in a real
life setting, showed that a 1-year administration
course of MEP in severe asthma could reduce the
exacerbation rate, the dose of OCS taken by pa-
tients and the percentage of steroid-dependent
subjects, confirming what previously demon-
strated in randomized controlled trials (RCTs)23-25
and in real world studies.26,27 In fact, as already
shown, the introduction of MEP in severe
uncontrolled eosinophilic asthma. In particular we
observed a reduction of exacerbations of 81%,
after 1 year of therapy, and of OCS-dependent
patients (from 84% to 33%). In patients who
remained on chronic OCS, a significant reduction
of the dose was seen (4.73 mg (C.I. 7.13–2.24;
p ¼ 0.0002).
The effect of the drug in reducing exacerbations
is relevant in pharmacoeconomics terms. The total
mean annual cost per patient pre-MEP was esti-
mated in V 3,996, where the management of ex-
acerbations played a crucial role (V 1859)
corresponding per se to the 46.5% of the whole
cost. The management of exacerbations includes
not only the direct but also indirect costs related tolost working days, reduced productivity at work,
loss in economic terms of activities not directly
remunerative (voluntary work), estimated, in this
analysis in a mean of V 974 per year for each pa-
tient (Table 4). The introduction in therapy of MEP,
reduced by more than 80% both the costs of
exacerbation management and the indirect costs,
with a slight effect on the cost of drug therapy
(11%). The resulting cost savings per patient
treated with MEP, not considering the cost of
MEP, was V 2469 (95% CI 1945–2993), of which
62% attributable to the reduction in
exacerbations and hospitalizations, and 33% to
the reduction of productivity loss. This savings
represents an economic return of about 22% on
the starting investment ie, the cost of a year’s
treatment with MEP.
A secondary, but relevant observation, concerns
OCS therapy. It is well known that prolonged OCS
treatments are burdensome because of the side
effects, such as cataracts, diabetes, osteoporosis,
and hypertension.10–28 The use of OCS, therefore,
has important delayed consequences from a
pharmacoeconomic point of view, which could
not be captured in this study.29 Although OCS
are cheap per se, the cost associated with the
morbidity induced by these drugs represents a
very important shadow cost, particularly in
patients exposed to an overload of
corticosteroids. The analysis of an Italian
pharmacoeconomic model aimed at predicting
the cost of the adverse effects of corticosteroid
events in individuals with severe asthma in real
Volume 14, No. 2, Month 2021 7life30,31 showed that the total annual cost of OCS-
related events is approximately V 242 million.10 In
fact, compared to a rather high percentage of
steroid-dependent patients (72%), before the
introduction of MEP, with an average daily dosage
of 10  8.44 mg prednisone, the average cost for
this therapy was V 75, reduced to V 20 after 12
months of therapy. In this case, the analysis of the
one-year data alone is limiting with regard to the
economic benefits of steroid reduction, in fact,
analysing only the direct costs, related to what is
saved in terms of expenditure for steroid therapy,
an annual saving of just over V 50 per patient is
quite evident, a relatively low gain if compared to
an already described mean annual expenditure of
around V 4000. This type of pharmacoeconomic
analysis is limiting with regard to the real gain,
both in clinical and economic terms, of reducing
and/or suspending systemic steroid therapy.
Although the OCS-induced damages appear
already after short cycles,32 even at low dosages,
and greater damages are caused by prolonged
therapies over the years.10 Therefore, the effect,
both from the clinical and the
pharmacoeconomic point of view, could be
captured using a longer perspective, projecting
the savings related to the management of
common comorbidities linked to continuous
steroid treatment. Given this evidence, also
international documents, starting with the Global
Initiative for Asthma (GINA),3 strongly discourage
the use of OCS in asthma, allowing their
prescription only for short cycles or in patients
for whom the administration of biological drugs
has failed or is not possible.
The lifetime consequences of MEP were evalu-
ated in a recent cost-effectiveness analysis33–38 on
a population of adults with severe uncontrolled
asthma and eosinophilic inflammation. The
authors found that adding MEP to standard ICS
treatment resulted in an incremental cost per
exacerbation averted of $ 24,626 with a clinical
benefit of 23.96 exacerbations averted per
patients and 1.53 quality-adjusted life years
(QALYs) gained. However, while the cost offsets
were more than $ 18,000, the treatment cost
increased by about $ 600,000. Different scenario
analyses were investigated and the authors
concluded that adding MEP lowers exacerbation
rates and improves quality of life, but its valuewas heavily influenced by the ability to identify
responders and continue treatment for only those
who respond.
The main advantage of this study is that it was
conducted in real life, with retrospective and pro-
spective data, and not using pharmacoeconomic
mathematical models. The main limit is the small
sample, due to the fact that severe eosinophilic
asthma, eligible to MEP treatment is a rare disease
per se.
Overall, the economic savings of the drug, in a
real-life setting and in a limited observation over
time (12 months), could be seen mainly in the
reduction of exacerbation and hospitalization
costs, and also in the indirect costs such as lost
working days and savings in unpaid work activities.
The introduction of the drug alone was, therefore,
able to finance itself for a share of more than 20%
of the total annual cost, a share that if we analyse
the long-term effect, linked to the reduction in the
need to take OCS and, subsequently, the lower
comorbidities associated with it, can only increase.
In the long term, it can be assumed that, if the drug
maintains its stable efficacy over the years, further
economic savings should be expected. In addition,
by being able to treat patients before long periods
of OCS intake, savings in comorbidities, another
clinical and economical profit, would be possible.
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